Sapna Patel
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 45 | 2026 | 764 | 7.840 |
Why?
| | Skin Neoplasms | 21 | 2026 | 805 | 3.400 |
Why?
| | Ipilimumab | 10 | 2026 | 44 | 2.670 |
Why?
| | Uveal Neoplasms | 5 | 2024 | 16 | 2.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2026 | 1996 | 1.410 |
Why?
| | Neoadjuvant Therapy | 8 | 2026 | 474 | 1.330 |
Why?
| | Antineoplastic Agents, Immunological | 5 | 2023 | 200 | 1.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 11 | 2026 | 992 | 1.130 |
Why?
| | Programmed Cell Death 1 Receptor | 10 | 2026 | 268 | 1.060 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 245 | 0.930 |
Why?
| | Immunotherapy | 6 | 2026 | 669 | 0.890 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2025 | 20 | 0.860 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1334 | 0.800 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2026 | 155 | 0.730 |
Why?
| | CTLA-4 Antigen | 6 | 2026 | 105 | 0.720 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 53 | 0.660 |
Why?
| | Receptor, IGF Type 1 | 1 | 2020 | 64 | 0.640 |
Why?
| | Toll-Like Receptors | 1 | 2021 | 193 | 0.620 |
Why?
| | Dacarbazine | 3 | 2017 | 98 | 0.560 |
Why?
| | Interleukin-2 | 4 | 2025 | 434 | 0.470 |
Why?
| | Neoplasm Staging | 8 | 2024 | 1486 | 0.460 |
Why?
| | Neoplasm Metastasis | 7 | 2026 | 693 | 0.400 |
Why?
| | Lymphocyte Depletion | 2 | 2025 | 135 | 0.380 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2026 | 889 | 0.350 |
Why?
| | Choroid Neoplasms | 1 | 2011 | 9 | 0.340 |
Why?
| | Middle Aged | 26 | 2026 | 36359 | 0.340 |
Why?
| | Humans | 48 | 2026 | 145625 | 0.330 |
Why?
| | Immunotherapy, Adoptive | 3 | 2026 | 356 | 0.330 |
Why?
| | Aged | 22 | 2026 | 26251 | 0.320 |
Why?
| | Adult | 26 | 2026 | 40821 | 0.320 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2218 | 0.310 |
Why?
| | Quality of Life | 1 | 2023 | 3187 | 0.310 |
Why?
| | Male | 29 | 2026 | 73014 | 0.300 |
Why?
| | Quinazolines | 1 | 2011 | 267 | 0.300 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2025 | 429 | 0.300 |
Why?
| | Mucous Membrane | 3 | 2025 | 129 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 2 | 2016 | 982 | 0.290 |
Why?
| | Combined Modality Therapy | 6 | 2026 | 1269 | 0.270 |
Why?
| | Female | 30 | 2026 | 79080 | 0.270 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8351 | 0.260 |
Why?
| | Antigen-Presenting Cells | 1 | 2026 | 161 | 0.230 |
Why?
| | Interleukin-7 | 1 | 2026 | 66 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 50 | 0.230 |
Why?
| | Carcinoma, Renal Cell | 2 | 2019 | 229 | 0.220 |
Why?
| | Lymph Node Excision | 1 | 2026 | 173 | 0.210 |
Why?
| | Indolizines | 1 | 2024 | 13 | 0.210 |
Why?
| | Cyclic N-Oxides | 1 | 2024 | 32 | 0.210 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
| | Adjuvants, Immunologic | 2 | 2023 | 243 | 0.210 |
Why?
| | Imidazoles | 3 | 2024 | 244 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 767 | 0.190 |
Why?
| | Kidney Neoplasms | 2 | 2019 | 417 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 266 | 0.190 |
Why?
| | Prognosis | 7 | 2026 | 4331 | 0.190 |
Why?
| | Disease-Free Survival | 5 | 2018 | 777 | 0.190 |
Why?
| | Neoplasms | 4 | 2021 | 2944 | 0.180 |
Why?
| | Treatment Outcome | 9 | 2025 | 11744 | 0.170 |
Why?
| | Dietary Fiber | 1 | 2021 | 59 | 0.170 |
Why?
| | Urethral Neoplasms | 1 | 2021 | 3 | 0.170 |
Why?
| | Vaginal Neoplasms | 1 | 2021 | 20 | 0.170 |
Why?
| | Probiotics | 1 | 2021 | 61 | 0.170 |
Why?
| | Oximes | 2 | 2018 | 26 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2018 | 230 | 0.160 |
Why?
| | Rare Diseases | 1 | 2021 | 115 | 0.160 |
Why?
| | Pyrimidinones | 2 | 2018 | 124 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2021 | 163 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2026 | 929 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2021 | 161 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1156 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2023 | 466 | 0.140 |
Why?
| | Pyridones | 2 | 2018 | 210 | 0.140 |
Why?
| | Interleukin-9 | 1 | 2018 | 12 | 0.140 |
Why?
| | Carboplatin | 1 | 2018 | 168 | 0.140 |
Why?
| | Antibodies, Monoclonal | 3 | 2026 | 1511 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2024 | 774 | 0.130 |
Why?
| | T-Lymphocytes | 3 | 2021 | 2007 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2021 | 507 | 0.130 |
Why?
| | Disease Progression | 2 | 2023 | 2857 | 0.130 |
Why?
| | Paclitaxel | 1 | 2018 | 258 | 0.130 |
Why?
| | Mutation | 4 | 2018 | 4082 | 0.120 |
Why?
| | Immunomodulation | 1 | 2016 | 98 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2016 | 167 | 0.110 |
Why?
| | Texas | 2 | 2018 | 279 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 409 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 306 | 0.100 |
Why?
| | Survival Rate | 3 | 2026 | 2078 | 0.100 |
Why?
| | Early Detection of Cancer | 2 | 2016 | 501 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 446 | 0.100 |
Why?
| | Genetic Testing | 1 | 2016 | 491 | 0.090 |
Why?
| | Research | 1 | 2016 | 421 | 0.090 |
Why?
| | Young Adult | 7 | 2021 | 14240 | 0.090 |
Why?
| | Risk Factors | 2 | 2021 | 10840 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2674 | 0.070 |
Why?
| | Survival Analysis | 3 | 2018 | 1372 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2022 | 1034 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 3538 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2021 | 328 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2026 | 1361 | 0.070 |
Why?
| | Administration, Oral | 1 | 2011 | 867 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2011 | 636 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 959 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2455 | 0.060 |
Why?
| | Time Factors | 2 | 2021 | 7079 | 0.060 |
Why?
| | Cisplatin | 2 | 2021 | 346 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2026 | 143 | 0.060 |
Why?
| | Lymphatic Metastasis | 1 | 2026 | 335 | 0.050 |
Why?
| | Biomarkers | 1 | 2016 | 4329 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5397 | 0.050 |
Why?
| | Immunologic Memory | 1 | 2026 | 369 | 0.050 |
Why?
| | New York | 1 | 2023 | 127 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 212 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1073 | 0.050 |
Why?
| | Cohort Studies | 3 | 2021 | 6045 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 291 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2016 | 1709 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2026 | 17291 | 0.040 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2021 | 27 | 0.040 |
Why?
| | MART-1 Antigen | 1 | 2021 | 9 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2021 | 60 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 928 | 0.040 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 21 | 0.040 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 106 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 112 | 0.040 |
Why?
| | Mice | 3 | 2024 | 18266 | 0.040 |
Why?
| | Hydrolases | 1 | 2021 | 42 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 6021 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3678 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 209 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 676 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 394 | 0.040 |
Why?
| | Feces | 1 | 2021 | 494 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2018 | 216 | 0.030 |
Why?
| | Mohs Surgery | 1 | 2018 | 30 | 0.030 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 48 | 0.030 |
Why?
| | Standard of Care | 1 | 2018 | 81 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 2018 | 103 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2497 | 0.030 |
Why?
| | Ribosomal Protein S6 | 1 | 2016 | 18 | 0.030 |
Why?
| | Clone Cells | 1 | 2017 | 259 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2016 | 76 | 0.030 |
Why?
| | Taxoids | 1 | 2016 | 115 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2016 | 70 | 0.030 |
Why?
| | Gene Dosage | 1 | 2017 | 146 | 0.030 |
Why?
| | Cell-Free System | 1 | 2016 | 54 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 503 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2017 | 189 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 133 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2021 | 649 | 0.030 |
Why?
| | Apoptosis | 1 | 2024 | 2436 | 0.030 |
Why?
| | Animals | 3 | 2024 | 38030 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 169 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 288 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 494 | 0.030 |
Why?
| | Genome | 1 | 2017 | 307 | 0.030 |
Why?
| | Macrophages | 1 | 2022 | 1530 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 560 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 415 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4565 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2016 | 427 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2014 | 201 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6050 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1717 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1992 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22451 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2018 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1790 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 8087 | 0.010 |
Why?
| | Signal Transduction | 1 | 2016 | 5234 | 0.010 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|